nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR7—myenteric nerve plexus—systemic scleroderma	0.0497	0.201	CbGeAlD
Lurasidone—HTR7—pulmonary artery—systemic scleroderma	0.0352	0.143	CbGeAlD
Lurasidone—HTR2A—myenteric nerve plexus—systemic scleroderma	0.031	0.126	CbGeAlD
Lurasidone—HTR2A—pulmonary artery—systemic scleroderma	0.0219	0.089	CbGeAlD
Lurasidone—HTR7—artery—systemic scleroderma	0.013	0.0529	CbGeAlD
Lurasidone—HTR7—endothelium—systemic scleroderma	0.011	0.0447	CbGeAlD
Lurasidone—HTR7—blood vessel—systemic scleroderma	0.0102	0.0412	CbGeAlD
Lurasidone—HTR2A—artery—systemic scleroderma	0.00813	0.033	CbGeAlD
Lurasidone—HTR2A—endothelium—systemic scleroderma	0.00687	0.0279	CbGeAlD
Lurasidone—HTR2A—blood vessel—systemic scleroderma	0.00633	0.0257	CbGeAlD
Lurasidone—HTR7—connective tissue—systemic scleroderma	0.00521	0.0211	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—systemic scleroderma	0.00476	0.0193	CbGeAlD
Lurasidone—ADRA2A—connective tissue—systemic scleroderma	0.00382	0.0155	CbGeAlD
Lurasidone—HTR7—digestive system—systemic scleroderma	0.00376	0.0153	CbGeAlD
Lurasidone—HTR7—tendon—systemic scleroderma	0.00358	0.0145	CbGeAlD
Lurasidone—ADRA2C—tendon—systemic scleroderma	0.00329	0.0133	CbGeAlD
Lurasidone—HTR2A—connective tissue—systemic scleroderma	0.00325	0.0132	CbGeAlD
Lurasidone—HTR7—lung—systemic scleroderma	0.00314	0.0127	CbGeAlD
Lurasidone—HTR2A—smooth muscle tissue—systemic scleroderma	0.00297	0.012	CbGeAlD
Lurasidone—DRD2—lung—systemic scleroderma	0.00297	0.012	CbGeAlD
Lurasidone—ADRA2C—lung—systemic scleroderma	0.00289	0.0117	CbGeAlD
Lurasidone—ADRA2A—tendon—systemic scleroderma	0.00263	0.0106	CbGeAlD
Lurasidone—HTR2A—digestive system—systemic scleroderma	0.00235	0.00951	CbGeAlD
Lurasidone—ADRA2A—lung—systemic scleroderma	0.0023	0.00934	CbGeAlD
Lurasidone—HTR2A—tendon—systemic scleroderma	0.00223	0.00905	CbGeAlD
Lurasidone—CYP3A4—digestive system—systemic scleroderma	0.00217	0.00881	CbGeAlD
Lurasidone—HTR2A—lung—systemic scleroderma	0.00196	0.00794	CbGeAlD
Lurasidone—Anaemia—Lisinopril—systemic scleroderma	0.00111	0.00147	CcSEcCtD
Lurasidone—Skin disorder—Leflunomide—systemic scleroderma	0.0011	0.00146	CcSEcCtD
Lurasidone—Hyperhidrosis—Leflunomide—systemic scleroderma	0.0011	0.00146	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.0011	0.00145	CcSEcCtD
Lurasidone—Angioedema—Lisinopril—systemic scleroderma	0.00109	0.00145	CcSEcCtD
Lurasidone—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00145	CcSEcCtD
Lurasidone—Abdominal pain—Captopril—systemic scleroderma	0.00109	0.00145	CcSEcCtD
Lurasidone—Nausea—Pentoxifylline—systemic scleroderma	0.00108	0.00143	CcSEcCtD
Lurasidone—Malaise—Lisinopril—systemic scleroderma	0.00108	0.00143	CcSEcCtD
Lurasidone—Infection—Mycophenolic acid—systemic scleroderma	0.00108	0.00143	CcSEcCtD
Lurasidone—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00108	0.00143	CcSEcCtD
Lurasidone—Vertigo—Lisinopril—systemic scleroderma	0.00107	0.00143	CcSEcCtD
Lurasidone—Diarrhoea—Mometasone—systemic scleroderma	0.00107	0.00143	CcSEcCtD
Lurasidone—Syncope—Lisinopril—systemic scleroderma	0.00107	0.00142	CcSEcCtD
Lurasidone—Leukopenia—Lisinopril—systemic scleroderma	0.00107	0.00142	CcSEcCtD
Lurasidone—Shock—Mycophenolic acid—systemic scleroderma	0.00107	0.00142	CcSEcCtD
Lurasidone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00106	0.00141	CcSEcCtD
Lurasidone—Hypotension—Leflunomide—systemic scleroderma	0.00106	0.00141	CcSEcCtD
Lurasidone—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00106	0.0014	CcSEcCtD
Lurasidone—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00105	0.0014	CcSEcCtD
Lurasidone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00105	0.0014	CcSEcCtD
Lurasidone—Loss of consciousness—Lisinopril—systemic scleroderma	0.00105	0.0014	CcSEcCtD
Lurasidone—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00139	CcSEcCtD
Lurasidone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00105	0.00139	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00104	0.00138	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00104	0.00138	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00104	0.00137	CcSEcCtD
Lurasidone—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00137	CcSEcCtD
Lurasidone—Insomnia—Leflunomide—systemic scleroderma	0.00103	0.00136	CcSEcCtD
Lurasidone—Myalgia—Lisinopril—systemic scleroderma	0.00102	0.00135	CcSEcCtD
Lurasidone—Anxiety—Lisinopril—systemic scleroderma	0.00101	0.00135	CcSEcCtD
Lurasidone—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00135	CcSEcCtD
Lurasidone—Dyspnoea—Leflunomide—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Hypotension—Mycophenolic acid—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Lethargy—Methotrexate—systemic scleroderma	0.00101	0.00134	CcSEcCtD
Lurasidone—Dyspepsia—Leflunomide—systemic scleroderma	0.001	0.00133	CcSEcCtD
Lurasidone—Vomiting—Mometasone—systemic scleroderma	0.000998	0.00132	CcSEcCtD
Lurasidone—Dry mouth—Lisinopril—systemic scleroderma	0.000996	0.00132	CcSEcCtD
Lurasidone—Rash—Mometasone—systemic scleroderma	0.00099	0.00131	CcSEcCtD
Lurasidone—Asthenia—Captopril—systemic scleroderma	0.000989	0.00131	CcSEcCtD
Lurasidone—Dermatitis—Mometasone—systemic scleroderma	0.000989	0.00131	CcSEcCtD
Lurasidone—Decreased appetite—Leflunomide—systemic scleroderma	0.000988	0.00131	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000987	0.00131	CcSEcCtD
Lurasidone—Osteoarthritis—Methotrexate—systemic scleroderma	0.000986	0.00131	CcSEcCtD
Lurasidone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000984	0.00131	CcSEcCtD
Lurasidone—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000982	0.0013	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000981	0.0013	CcSEcCtD
Lurasidone—Insomnia—Mycophenolic acid—systemic scleroderma	0.00098	0.0013	CcSEcCtD
Lurasidone—Fatigue—Leflunomide—systemic scleroderma	0.000979	0.0013	CcSEcCtD
Lurasidone—Pruritus—Captopril—systemic scleroderma	0.000975	0.00129	CcSEcCtD
Lurasidone—Infection—Lisinopril—systemic scleroderma	0.00097	0.00129	CcSEcCtD
Lurasidone—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00129	CcSEcCtD
Lurasidone—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000966	0.00128	CcSEcCtD
Lurasidone—Somnolence—Mycophenolic acid—systemic scleroderma	0.000963	0.00128	CcSEcCtD
Lurasidone—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000963	0.00128	CcSEcCtD
Lurasidone—Shock—Lisinopril—systemic scleroderma	0.00096	0.00127	CcSEcCtD
Lurasidone—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000958	0.00127	CcSEcCtD
Lurasidone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000954	0.00127	CcSEcCtD
Lurasidone—Neutropenia—Prednisone—systemic scleroderma	0.000953	0.00127	CcSEcCtD
Lurasidone—Tachycardia—Lisinopril—systemic scleroderma	0.000953	0.00126	CcSEcCtD
Lurasidone—Abdominal pain—Azathioprine—systemic scleroderma	0.000951	0.00126	CcSEcCtD
Lurasidone—Skin disorder—Lisinopril—systemic scleroderma	0.000948	0.00126	CcSEcCtD
Lurasidone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000945	0.00125	CcSEcCtD
Lurasidone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000944	0.00125	CcSEcCtD
Lurasidone—Diarrhoea—Captopril—systemic scleroderma	0.000943	0.00125	CcSEcCtD
Lurasidone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000942	0.00125	CcSEcCtD
Lurasidone—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000942	0.00125	CcSEcCtD
Lurasidone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00094	0.00125	CcSEcCtD
Lurasidone—Erectile dysfunction—Prednisone—systemic scleroderma	0.000939	0.00125	CcSEcCtD
Lurasidone—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000938	0.00125	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000936	0.00124	CcSEcCtD
Lurasidone—Fatigue—Mycophenolic acid—systemic scleroderma	0.000934	0.00124	CcSEcCtD
Lurasidone—Nausea—Mometasone—systemic scleroderma	0.000932	0.00124	CcSEcCtD
Lurasidone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000929	0.00123	CcSEcCtD
Lurasidone—Weight increased—Prednisone—systemic scleroderma	0.000928	0.00123	CcSEcCtD
Lurasidone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000921	0.00122	CcSEcCtD
Lurasidone—Hyperglycaemia—Prednisone—systemic scleroderma	0.00092	0.00122	CcSEcCtD
Lurasidone—Hypotension—Lisinopril—systemic scleroderma	0.000912	0.00121	CcSEcCtD
Lurasidone—Dizziness—Captopril—systemic scleroderma	0.000912	0.00121	CcSEcCtD
Lurasidone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000908	0.00121	CcSEcCtD
Lurasidone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000905	0.0012	CcSEcCtD
Lurasidone—Abdominal pain—Leflunomide—systemic scleroderma	0.000898	0.00119	CcSEcCtD
Lurasidone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000892	0.00118	CcSEcCtD
Lurasidone—Breast disorder—Methotrexate—systemic scleroderma	0.000891	0.00118	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000889	0.00118	CcSEcCtD
Lurasidone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000889	0.00118	CcSEcCtD
Lurasidone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000886	0.00118	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000886	0.00118	CcSEcCtD
Lurasidone—Insomnia—Lisinopril—systemic scleroderma	0.000883	0.00117	CcSEcCtD
Lurasidone—Vomiting—Captopril—systemic scleroderma	0.000876	0.00116	CcSEcCtD
Lurasidone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000873	0.00116	CcSEcCtD
Lurasidone—Dyspnoea—Lisinopril—systemic scleroderma	0.00087	0.00116	CcSEcCtD
Lurasidone—Rash—Captopril—systemic scleroderma	0.000869	0.00115	CcSEcCtD
Lurasidone—Dermatitis—Captopril—systemic scleroderma	0.000868	0.00115	CcSEcCtD
Lurasidone—Somnolence—Lisinopril—systemic scleroderma	0.000868	0.00115	CcSEcCtD
Lurasidone—Dyspepsia—Lisinopril—systemic scleroderma	0.000859	0.00114	CcSEcCtD
Lurasidone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000857	0.00114	CcSEcCtD
Lurasidone—Infection—Mycophenolate mofetil—systemic scleroderma	0.00085	0.00113	CcSEcCtD
Lurasidone—Decreased appetite—Lisinopril—systemic scleroderma	0.000849	0.00113	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—systemic scleroderma	0.000844	0.00112	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000843	0.00112	CcSEcCtD
Lurasidone—Fatigue—Lisinopril—systemic scleroderma	0.000842	0.00112	CcSEcCtD
Lurasidone—Shock—Mycophenolate mofetil—systemic scleroderma	0.000841	0.00112	CcSEcCtD
Lurasidone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000839	0.00111	CcSEcCtD
Lurasidone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000835	0.00111	CcSEcCtD
Lurasidone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000831	0.0011	CcSEcCtD
Lurasidone—Bradycardia—Prednisone—systemic scleroderma	0.000831	0.0011	CcSEcCtD
Lurasidone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000827	0.0011	CcSEcCtD
Lurasidone—Diarrhoea—Azathioprine—systemic scleroderma	0.000823	0.00109	CcSEcCtD
Lurasidone—Nausea—Captopril—systemic scleroderma	0.000819	0.00109	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000817	0.00108	CcSEcCtD
Lurasidone—Asthenia—Leflunomide—systemic scleroderma	0.000815	0.00108	CcSEcCtD
Lurasidone—Pruritus—Leflunomide—systemic scleroderma	0.000804	0.00107	CcSEcCtD
Lurasidone—Connective tissue disorder—Prednisone—systemic scleroderma	0.000802	0.00106	CcSEcCtD
Lurasidone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000799	0.00106	CcSEcCtD
Lurasidone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000798	0.00106	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—systemic scleroderma	0.000797	0.00106	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—systemic scleroderma	0.000797	0.00106	CcSEcCtD
Lurasidone—Dizziness—Azathioprine—systemic scleroderma	0.000796	0.00106	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000785	0.00104	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000779	0.00103	CcSEcCtD
Lurasidone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000778	0.00103	CcSEcCtD
Lurasidone—Diarrhoea—Leflunomide—systemic scleroderma	0.000777	0.00103	CcSEcCtD
Lurasidone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000774	0.00103	CcSEcCtD
Lurasidone—Abdominal pain—Lisinopril—systemic scleroderma	0.000772	0.00102	CcSEcCtD
Lurasidone—Pruritus—Mycophenolic acid—systemic scleroderma	0.000767	0.00102	CcSEcCtD
Lurasidone—Vomiting—Azathioprine—systemic scleroderma	0.000765	0.00102	CcSEcCtD
Lurasidone—Eye disorder—Prednisone—systemic scleroderma	0.000763	0.00101	CcSEcCtD
Lurasidone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000763	0.00101	CcSEcCtD
Lurasidone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00076	0.00101	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—systemic scleroderma	0.00076	0.00101	CcSEcCtD
Lurasidone—Infestation—Methotrexate—systemic scleroderma	0.00076	0.00101	CcSEcCtD
Lurasidone—Rash—Azathioprine—systemic scleroderma	0.000759	0.00101	CcSEcCtD
Lurasidone—Dermatitis—Azathioprine—systemic scleroderma	0.000758	0.00101	CcSEcCtD
Lurasidone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000753	0.000999	CcSEcCtD
Lurasidone—Dizziness—Leflunomide—systemic scleroderma	0.000751	0.000997	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—systemic scleroderma	0.000747	0.000991	CcSEcCtD
Lurasidone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000744	0.000987	CcSEcCtD
Lurasidone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000742	0.000984	CcSEcCtD
Lurasidone—Angiopathy—Prednisone—systemic scleroderma	0.00074	0.000983	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000738	0.00098	CcSEcCtD
Lurasidone—Arrhythmia—Prednisone—systemic scleroderma	0.000729	0.000968	CcSEcCtD
Lurasidone—Vomiting—Leflunomide—systemic scleroderma	0.000722	0.000959	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000718	0.000954	CcSEcCtD
Lurasidone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000717	0.000951	CcSEcCtD
Lurasidone—Rash—Leflunomide—systemic scleroderma	0.000716	0.000951	CcSEcCtD
Lurasidone—Dermatitis—Leflunomide—systemic scleroderma	0.000716	0.00095	CcSEcCtD
Lurasidone—Mental disorder—Prednisone—systemic scleroderma	0.000715	0.000949	CcSEcCtD
Lurasidone—Nausea—Azathioprine—systemic scleroderma	0.000715	0.000948	CcSEcCtD
Lurasidone—Malnutrition—Prednisone—systemic scleroderma	0.00071	0.000943	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—systemic scleroderma	0.000709	0.000941	CcSEcCtD
Lurasidone—Asthenia—Lisinopril—systemic scleroderma	0.0007	0.00093	CcSEcCtD
Lurasidone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000699	0.000928	CcSEcCtD
Lurasidone—Pruritus—Lisinopril—systemic scleroderma	0.000691	0.000917	CcSEcCtD
Lurasidone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000689	0.000915	CcSEcCtD
Lurasidone—Rash—Mycophenolic acid—systemic scleroderma	0.000683	0.000907	CcSEcCtD
Lurasidone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000683	0.000906	CcSEcCtD
Lurasidone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000676	0.000897	CcSEcCtD
Lurasidone—Nausea—Leflunomide—systemic scleroderma	0.000675	0.000896	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000674	0.000894	CcSEcCtD
Lurasidone—Vision blurred—Prednisone—systemic scleroderma	0.000669	0.000889	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—systemic scleroderma	0.000669	0.000887	CcSEcCtD
Lurasidone—Diarrhoea—Lisinopril—systemic scleroderma	0.000668	0.000887	CcSEcCtD
Lurasidone—Anaemia—Prednisone—systemic scleroderma	0.000657	0.000871	CcSEcCtD
Lurasidone—Agitation—Prednisone—systemic scleroderma	0.000653	0.000866	CcSEcCtD
Lurasidone—Angioedema—Prednisone—systemic scleroderma	0.000649	0.000862	CcSEcCtD
Lurasidone—Dizziness—Lisinopril—systemic scleroderma	0.000646	0.000857	CcSEcCtD
Lurasidone—Nausea—Mycophenolic acid—systemic scleroderma	0.000644	0.000854	CcSEcCtD
Lurasidone—Malaise—Prednisone—systemic scleroderma	0.000641	0.00085	CcSEcCtD
Lurasidone—Vertigo—Prednisone—systemic scleroderma	0.000638	0.000847	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—systemic scleroderma	0.000637	0.000846	CcSEcCtD
Lurasidone—Syncope—Prednisone—systemic scleroderma	0.000637	0.000846	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—systemic scleroderma	0.000633	0.00084	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisone—systemic scleroderma	0.000624	0.000829	CcSEcCtD
Lurasidone—Vomiting—Lisinopril—systemic scleroderma	0.000621	0.000824	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—systemic scleroderma	0.000619	0.000821	CcSEcCtD
Lurasidone—Rash—Lisinopril—systemic scleroderma	0.000616	0.000817	CcSEcCtD
Lurasidone—Convulsion—Prednisone—systemic scleroderma	0.000615	0.000817	CcSEcCtD
Lurasidone—Dermatitis—Lisinopril—systemic scleroderma	0.000615	0.000816	CcSEcCtD
Lurasidone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000614	0.000814	CcSEcCtD
Lurasidone—Hypertension—Prednisone—systemic scleroderma	0.000613	0.000814	CcSEcCtD
Lurasidone—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000605	0.000803	CcSEcCtD
Lurasidone—Myalgia—Prednisone—systemic scleroderma	0.000605	0.000803	CcSEcCtD
Lurasidone—Anxiety—Prednisone—systemic scleroderma	0.000603	0.0008	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000601	0.000797	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—systemic scleroderma	0.000597	0.000793	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—systemic scleroderma	0.000594	0.000788	CcSEcCtD
Lurasidone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000585	0.000777	CcSEcCtD
Lurasidone—Nausea—Lisinopril—systemic scleroderma	0.00058	0.00077	CcSEcCtD
Lurasidone—Infection—Prednisone—systemic scleroderma	0.000576	0.000764	CcSEcCtD
Lurasidone—Back pain—Methotrexate—systemic scleroderma	0.000574	0.000762	CcSEcCtD
Lurasidone—Shock—Prednisone—systemic scleroderma	0.00057	0.000757	CcSEcCtD
Lurasidone—Nervous system disorder—Prednisone—systemic scleroderma	0.000569	0.000755	CcSEcCtD
Lurasidone—Tachycardia—Prednisone—systemic scleroderma	0.000566	0.000751	CcSEcCtD
Lurasidone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000566	0.000751	CcSEcCtD
Lurasidone—Skin disorder—Prednisone—systemic scleroderma	0.000563	0.000747	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisone—systemic scleroderma	0.00056	0.000744	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—systemic scleroderma	0.00056	0.000743	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—systemic scleroderma	0.000549	0.000728	CcSEcCtD
Lurasidone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000544	0.000722	CcSEcCtD
Lurasidone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000539	0.000716	CcSEcCtD
Lurasidone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000539	0.000715	CcSEcCtD
Lurasidone—Malaise—Methotrexate—systemic scleroderma	0.000535	0.000711	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—systemic scleroderma	0.000533	0.000708	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—systemic scleroderma	0.000531	0.000705	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000528	0.000701	CcSEcCtD
Lurasidone—Insomnia—Prednisone—systemic scleroderma	0.000524	0.000696	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—systemic scleroderma	0.000514	0.000683	CcSEcCtD
Lurasidone—Dyspepsia—Prednisone—systemic scleroderma	0.00051	0.000677	CcSEcCtD
Lurasidone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000508	0.000674	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—systemic scleroderma	0.000505	0.000671	CcSEcCtD
Lurasidone—Decreased appetite—Prednisone—systemic scleroderma	0.000504	0.000669	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000502	0.000666	CcSEcCtD
Lurasidone—Fatigue—Prednisone—systemic scleroderma	0.0005	0.000663	CcSEcCtD
Lurasidone—Infection—Methotrexate—systemic scleroderma	0.000481	0.000639	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000475	0.000631	CcSEcCtD
Lurasidone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000474	0.000629	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—systemic scleroderma	0.000471	0.000625	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000468	0.000622	CcSEcCtD
Lurasidone—Abdominal pain—Prednisone—systemic scleroderma	0.000458	0.000608	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—systemic scleroderma	0.000453	0.000601	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000441	0.000586	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—systemic scleroderma	0.000438	0.000582	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—systemic scleroderma	0.000432	0.000573	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—systemic scleroderma	0.000431	0.000572	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—systemic scleroderma	0.000427	0.000566	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—systemic scleroderma	0.000421	0.000559	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000418	0.000555	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—systemic scleroderma	0.000418	0.000554	CcSEcCtD
Lurasidone—Asthenia—Prednisone—systemic scleroderma	0.000416	0.000552	CcSEcCtD
Lurasidone—Pruritus—Prednisone—systemic scleroderma	0.00041	0.000544	CcSEcCtD
Lurasidone—Diarrhoea—Prednisone—systemic scleroderma	0.000397	0.000527	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000396	0.000526	CcSEcCtD
Lurasidone—Dizziness—Prednisone—systemic scleroderma	0.000383	0.000509	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—systemic scleroderma	0.000383	0.000508	CcSEcCtD
Lurasidone—Vomiting—Prednisone—systemic scleroderma	0.000369	0.000489	CcSEcCtD
Lurasidone—Rash—Prednisone—systemic scleroderma	0.000366	0.000485	CcSEcCtD
Lurasidone—Dermatitis—Prednisone—systemic scleroderma	0.000365	0.000485	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—systemic scleroderma	0.000348	0.000461	CcSEcCtD
Lurasidone—Nausea—Prednisone—systemic scleroderma	0.000344	0.000457	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—systemic scleroderma	0.000343	0.000455	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—systemic scleroderma	0.000332	0.00044	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—systemic scleroderma	0.00032	0.000425	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—systemic scleroderma	0.000308	0.000409	CcSEcCtD
Lurasidone—Rash—Methotrexate—systemic scleroderma	0.000306	0.000405	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—systemic scleroderma	0.000305	0.000405	CcSEcCtD
Lurasidone—Nausea—Methotrexate—systemic scleroderma	0.000288	0.000382	CcSEcCtD
